Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:UMRX

Cogent Biosciences (UMRX) Stock Price, News & Analysis

Cogent Biosciences logo

About Cogent Biosciences Stock (NASDAQ:UMRX)

Advanced Chart

Key Stats

Today's Range
$7.15
$7.48
50-Day Range
$2.35
$13.01
52-Week Range
$0.29
$3.72
Volume
1.99 million shs
Average Volume
1.22 million shs
Market Capitalization
$304.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Receive UMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

UMRX Stock News Headlines

Top Picks for Trump’s Pro-Crypto America
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
Cogent Biosciences (COGT) Initiated with a Buy at Scotiabank
See More Headlines

UMRX Stock Analysis - Frequently Asked Questions

Cogent Biosciences, Inc. (NASDAQ:UMRX) announced its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.03. The business had revenue of $0.53 million for the quarter. Cogent Biosciences had a negative net margin of 96.84% and a negative trailing twelve-month return on equity of 87.78%.

Cogent Biosciences (UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/11/2020
Today
7/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UMRX
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$31.83 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.50 million
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
6.90

Miscellaneous

Free Float
N/A
Market Cap
$304.93 million
Optionable
Not Optionable
Beta
3.93
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:UMRX) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners